Global Viral Vaccine Market was valued at USD XX Billion in the year 2020. Global Viral Vaccine Market is further estimated to grow at a CAGR of XX% from 2020 to reach USD XX Billion by the year 2030. The North America region holds the highest market share in 2020 and the Asia Pacific is considered as the fastest growing market in the forecasted period. At a country level, NA, Europe, China are projected to grow strongly in the coming years due to increasing density of population and funding through Research and Development.

The Global Viral Vaccine Report 2021-2030 covers business mix, market opportunities and challenges, new product development, key market regulations’ information, analysis of new products from the market players and key market trends, market share analysis for key players, supply chain and value chain analysis, product and Material trends, pricing analysis, emerging applications, technologies and major recent developments. This information has also been provided for the major country markets in these regions. Market shares, size and growth potential are assessed for these major country markets. Market opportunities, challenges, government regulations, market share analysis by major competitors, recent major market developments (product launches, M&A, partnerships, etc.) and other information have been covered for the major country markets listed in this section.

On the basis of Type, the market is divided as Attenuated Vaccine, Inactivated Vaccine, , . In which Left Regular Lay for the largest market share due to increasing demand in future market trends. Regional breakdown and deep analysis of each of the aforesaid segments is included for North America, South America, Europe, Asia-Pacific, Africa, Middle East and ROW.

Market player analysis of key companies such as and others.

Particular	Scope
Region	North America: United States, Canada, and Mexico. South & Central America: Argentina, Chile, and Brazil. Middle East & Africa: Saudi Arabia, UAE, Turkey, Egypt and South Africa. Europe: UK, France, Italy, Germany, Spain, and Russia. Asia-Pacific: India, China, Japan, South Korea, Indonesia, Singapore, Australia and Southeast Asia.
Historic Year	2016-2020
Base Year	2021
Forecast Year	2022 - 2030
Quantitative units	Revenue in USD million/billion and CAGR from 2022 to 2030
Report coverage	Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered	Component, technology, type, application, region

This research report will answer the following questions:

• Which are the major players and what are their business plans on a global scale?
• Which are the major industry regions?
• Growth opportunities and trend analysis?
• Competition strategy and market share analysis?

1 Introduction

1.1 Objectives

1.2 Research Methodology

1.2.1 Secondary Data

1.2.2 Primary Data

1.2.3 Market Size Estimation

1.2.4 Market Breakdown and Data Triangulation

1.3 Stakeholders

1.4 Research Assumptions

1.5 Limitation

2 Executive Summary

3 Market Outlook

3.1 Introduction

3.2 Opportunities Matrix

3.3 Market Challenges

3.4 Market Share Analysis

3.5 Value chain Analysis

3.6 Demand Side Analysis

3.7 Supply Side Analysis

3.8 Porter’s Five Forces Model

3.8.1 Degree of Competition

3.8.2 Bargaining Power of Buyers

3.8.3 Bargaining Power of Suppliers

3.8.4 Threat from Substitutes

3.8.5 Threat from New Entrants

4 Industry Trends

4.1 Product Life cycle

4.2 New Market Entry Strategy

4.3 PESTEL Analysis

4.4 Pricing Analysis

4.5 Trade Data

4.6 Technological overview

4.7 Future Outlook Market Trends

4.8 Macro-Economic Variables (Dependent and Independent Variables)

4.9 Multifactor Based Sensitivity Analysis

4.10 Regression Matrix

4.11 COVID-19 Impact Analyses

4.12 GE Matrix

5 GLOBAL Viral Vaccine TYPE ANALYSIS

5.1 INTRODUCTION

5.2 HISTORICAL MARKET TYPE ANALYSIS, 2015-2019

5.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030

5.4 Y-O-Y GROWTH TREND ANALYSIS

5.5.5 Attenuated Vaccine
5.5.6 Inactivated Vaccine

6 GLOBAL Viral Vaccine MARKET APPLICATION ANALYSIS

6.1 INTRODUCTION

6.2 HISTORICAL MARKET CONSTRUCTION ACTIVITY ANALYSIS, 2015-2019

6.3 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030

6.4 Y-O-Y GROWTH TREND ANALYSIS

6.5.5 Adults
6.5.6 Children

7 GLOBAL Viral Vaccine REGIONAL ANALYSIS

7.1 INTRODUCTION

7.2 NORTH AMERICA

7.2.1 NORTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019

7.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030

7.2.3 Y-O-Y GROWTH TREND ANALYSIS

7.2.4 U.S.

7.2.5 Canada

7.2.6 Mexico

7.3 ASIA-PACIFIC

7.2.1 APAC HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019

7.2.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030

7.2.3 Y-O-Y GROWTH TREND ANALYSIS

7.3.3 China

7.3.4 Japan

7.3.5 Korea

7.3.6 India

7.3.7 Southeast Asia

7.4 MIDDLE EAST AND AFRICA

7.4.1 MIDDLE EAST AND AFRICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019

7.4.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030

7.4.3 Y-O-Y GROWTH TREND ANALYSIS

7.4.4 Saudi Arabia

7.4.5 UAE

7.4.6 Egypt

7.4.7 Nigeria

7.4.8 South Africa

7.5 EUROPE

7.5.1 EUROPE HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019

7.5.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030

7.5.3 Y-O-Y GROWTH TREND ANALYSIS

7.5.4 Germany

7.5.5 France

7.5.6 UK

7.5.7 Russia

7.5.8 Italy

7.6 SOUTH AMERICA

7.6.1 SOUTH AMERICA HISTORICAL MARKET COUNTRY ANALYSIS, 2015-2019

7.6.2 CURRENT AND FUTURE MARKET VALUE (MILLION) PROJECTIONS, 2020–2030

7.6.3 Y-O-Y GROWTH TREND ANALYSIS

7.6.4 Brazil

7.6.5 Argentina

7.6.6 Columbia

8 MARKET PLAYERS

8.1 GSK

8.1.1 BUSINESS OVERVIEW

8.1.2 PRODUCT PORTFOLIO

8.1.3 RECENT DEVELOPMENTS

8.1.4 SWOT ANALYSIS

8.2.1 GSK
8.2.2 Merck
8.2.3 Novartis
8.2.4 Pfizer
8.2.5 Sanofi Pasteur
8.2.6 Bayer
8.2.7 Zoetis
8.2.8 AstraZeneca
8.2.9 Johnson & Johnson
8.2.10 CSL Limited
8.2.11 Astellas Pharma
8.2.12 Emergent BioSolutions
8.2.13 MedImmune
8.2.14 Serum Institute of India
8.2.15 Encephalitis 
8.2.16 Cochrane Collaboration
8.2.17 Sonic HealthPlus
8.2.18 Superdrug Health
8.2.19 CNBG
8.2.20 Changsheng Life
8.2.21 Baxter
8.2.22 ChengDa Bio
8.2.23 Boehringer Ingelheim
8.2.24 SINOVAC BIOTECH
8.2.25 Hissen
8.2.26 Walvax Biotechnology
8.2.27 Rong An
8.2.28 NuoCheng Bio
8.2.29 Hualan Bio
8.2.30 Tiantan Biological

9 ABOUT US

TABLE 1                GLOBAL Viral Vaccine REGIONAL ANALYSIS, 2020–2030 (USD MILLION)

TABLE 2                GLOBAL Viral Vaccine MARKET, 2020–2030, (USD MILLION)

TABLE 3                Viral Vaccine CURRENT AND FUTURE REGIONAL ANALYSIS,  2020–2030 (USD MILLION)

TABLE 4                GLOBAL Viral Vaccine HISTORICAL MARKET TYPE ANALYSIS,  2015-2019, (USD MILLION)

TABLE 5                Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)

TABLE 6                GLOBAL Viral Vaccine HISTORICAL MARKET APPLICATION ANALYSIS,  2015-2019, (USD MILLION)

TABLE 7                Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030 (USD MILLION)

TABLE 8                NORTH AMERICA Viral Vaccine HISTORICAL MARKET ANALYSIS,  2015-2019, (USD MILLION)

TABLE 9                NORTH AMERICA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030 (USD MILLION)

TABLE 10              NORTH AMERICA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)

TABLE 11              U.S. Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS, 2015–2020

TABLE 12              U.S. Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 13              U.S. Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 14              CANADA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 15              CANADA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 16              MEXICO Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 17              MEXICO Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 18              APAC Viral Vaccine HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)

TABLE 19              ASIA-PACIFIC Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030 (USD MILLION)

TABLE 20              ASIA-PACIFIC Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030 (USD MILLION)

TABLE 21              CHINA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 22              CHINA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 23              JAPAN Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 24              JAPAN Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 25              KOREA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 26              KOREA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 27              INDIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 28              INDIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 29              SOUTHEAST ASIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 30              SOUTHEAST ASIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

TABLE 31              MIDDLE EAST AND AFRICA Viral Vaccine HISTORICAL MARKET ANALYSIS,  2015-2019, (USD MILLION)

TABLE 32              MIDDLE EAST AND AFRICA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030 (USD MILLION)

TABLE 33              MIDDLE EAST AND AFRICA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)

TABLE 34              SAUDI ARABIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 35              SAUDI ARABIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 36              UAE Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 37              UAE Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 38              EGYPT Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 39              EGYPT Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 40              NIGERIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 41              NIGERIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 42              SOUTH AFRICA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 43              SOUTH AFRICA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 44              EUROPE Viral Vaccine HISTORICAL MARKET ANALYSIS, 2015-2019, (USD MILLION)

TABLE 45              EUROPE Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030 (USD MILLION)

TABLE 46              EUROPE Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030 (USD MILLION)

TABLE 47              GERMANY Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 48              GERMANY Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 49              FRANCE Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 50              FRANCE Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 51              UK Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 52              UK Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 53              RUSSIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 54              RUSSIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 55              ITALY Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 56              ITALY Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 57              SOUTH AMERICA Viral Vaccine HISTORICAL MARKET ANALYSIS,  2015-2019, (USD MILLION)

TABLE 58              SOUTH AMERICA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030 (USD MILLION)

TABLE 59              SOUTH AMERICA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030 (USD MILLION)

TABLE 60              BRAZIL Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 61              BRAZIL Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 62              ARGENTINA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 63              ARGENTINA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

TABLE 64              COLUMBIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

TABLE 65              COLUMBIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 1         GLOBAL Viral Vaccine MARKET, 2020–2030, (USD MILLION)

FIGURE 2         RESEARCH METHODOLOGY

FIGURE 3         GLOBAL Viral Vaccine CURRENT AND FUTURE MARKET,  2020–2030, (USD MILLION)

FIGURE 4         GLOBAL Viral Vaccine CURRENT AND FUTURE MARKET,  2020–2030, (USD MILLION)

FIGURE 5         MARKET OVERVIEW

FIGURE 6         SWOT ANALYSIS

FIGURE 7         MARKET SHARE ANALYSIS

FIGURE 8         SUPPLY CHAIN ANALYSIS

FIGURE 9         PORTER’S FIVE FORCES ANALYSIS

FIGURE 10        Viral Vaccine TYPE ANALYSIS

FIGURE 11        GLOBAL Viral Vaccine CURRENT AND FUTURE MARKET TYPE ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 12        Viral Vaccine APPLICATION ANALYSIS

FIGURE 13        GLOBAL Viral Vaccine CURRENT AND FUTURE MARKET APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 14        GLOBAL Viral Vaccine CURRENT AND FUTURE MARKET VOLUME SHARE REGIONAL ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 15        MARKET OVERVIEW, REGIONAL ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 16        MARKET SHARE BY COUNTRY

FIGURE 17        NORTH AMERICA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 18        NORTH AMERICA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 19        U.S. Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 20        U.S. Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 21        CANADA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 22        CANADA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 23        MEXICO Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 24        MEXICO Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 25        MARKET SHARE BY COUNTRY

FIGURE 26        APAC Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 27        APAC Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 28        CHINA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 29        CHINA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 30        JAPAN Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 31        JAPAN Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 32        KOREA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 33        KOREA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 34        INDIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 35        INDIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 36        SOUTHEAST ASIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 37        SOUTHEAST ASIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 38        MARKET SHARE BY COUNTRY

FIGURE 39        MIDDLE EAST AND AFRICA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 40        MIDDLE EAST AND AFRICA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 41        SAUDI ARABIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 42        SAUDI ARABIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 43        UAE Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 44        UAE Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 45        EGYPT Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 46        EGYPT Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 47        NIGERIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 48        NIGERIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 49        SOUTH AFRICA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 50        SOUTH AFRICA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 51        MARKET SHARE BY COUNTRY

FIGURE 52        EUROPE Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 53        EUROPE Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 54        GERMANY Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 55        GERMANY Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 56        FRANCE Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 57        FRANCE Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 58        UK Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 59        UK Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 60        RUSSIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 61        RUSSIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 62        ITALY Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 63        ITALY Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 64        MARKET SHARE BY COUNTRY

FIGURE 65        SOUTH AMERICA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 66        SOUTH AMERICA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 67        BRAZIL Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 68        BRAZIL Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 69        ARGENTINA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 70        ARGENTINA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 71        COLUMBIA Viral Vaccine CURRENT AND FUTURE TYPE ANALYSIS,  2020–2030, (USD MILLION)

FIGURE 72        COLUMBIA Viral Vaccine CURRENT AND FUTURE APPLICATION ANALYSIS, 2020–2030, (USD MILLION)

FIGURE 73        FINANCIAL OVERVIEW: